Fineline Cube

Follow:
14484 Articles
Livzon Pharmaceutical Group Inks Influenza Vaccine Patent Deal with South China Vaccine Corporation
CompanyDeals

Livzon Pharmaceutical Group Inks Influenza Vaccine Patent Deal with South China Vaccine Corporation

WuXi AppTec's Subsidiary Invests EUR 20 Million in Jeito II S.L.P. for Growth Expansion
CompanyDeals

WuXi AppTec’s Subsidiary Invests EUR 20 Million in Jeito II S.L.P. for Growth Expansion

TJ Biopharma and Jumpcan Pharmaceutical Announce NMPA Review of Eftansomatropin Alfa BLA
CompanyDrug

TJ Biopharma and Jumpcan Pharmaceutical Announce NMPA Review of Eftansomatropin Alfa BLA

AstraZeneca's Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer
CompanyDrug

AstraZeneca’s Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer

Amgen's Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL
CompanyDrug

Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL

Novartis' Fabhalta Demonstrates Positive Results in APPULSE-PNH Phase IIIb Study
CompanyDrug

Novartis’ Fabhalta Demonstrates Positive Results in APPULSE-PNH Phase IIIb Study

Jiaxing Faber Xintian Pharma Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion
CompanyDeals

Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion

Novo Holdings' Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion
CompanyDeals

Novo Holdings’ Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion

Johnson & Johnson's Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024
CompanyDrug

Johnson & Johnson’s Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024

AstraZeneca's Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC
CompanyDrug

AstraZeneca’s Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC

Duality Biologics' BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia
CompanyDrug

Duality Biologics’ BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia

Innovent Biologics' IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia
CompanyDrug

Innovent Biologics’ IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia